Cisplatin administration to gynecologic cancer patients: Long term effects on hearing

Abstract

BACKGROUND. Cisplatin is known to create an acute dose-related ototoxic effect.

Synergistic effect of melatonin and ghrelin in preventing cisplatin‐induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1 promoter in primordial follicles

“…Various studies have reported that chemotherapy causes premature ovarian failure and infertility by triggering exhaustion of the primordial follicle pool in the ovaries of young female cancer patients . Cisplatin ( Cis ‐diamminedichloroplatinum‐II) is a platinum‐based alkylating agent that is commonly used to treat patients with a variety of solid tumors and gynecologic malignancies . However, the clinical uses of cisplatin are limited due to serious side effects, including toxicity to the kidney, liver, brain, and nervous and reproductive systems .…”

Associations between dietary quality, noise, and hearing: Data from the National Health and Nutrition Examination Survey, 1999–2002

“…Across studies, one of the potential risk factors for hearing loss is sex, with males having worse thresholds than females, although the influence of sex are difficult to interpret given sex-based differences in noise history (see Marlenga et al, 2012; Mahboubi et al, 2013). Other potentially important risk factors include race/ethnicity (Lin et al, 2012), education /socioeconomic status (Agrawal et al, 2008; Henderson et al, 2011; Zhan et al, 2011), noise exposure (Agrawal et al, 2009; Zhan et al, 2011; Mahboubi et al, 2013), smoking and second-hand smoke (Cruickshanks et al, 1998; Fabry et al, 2011), diabetes (Bainbridge et al, 2008), cardiovascular health (Agrawal et al, 2009; Nash et al, 2011), ototoxic drugs (Laurell et al, 1996), and there are some genes associated with vulnerability to hearing loss based on population studies (for reviews, see Liu & Yan, 2007; Uchida et al, 2011). The selection of modifying factors to include in these studies is a significant issue.…”

Neurotoxicity Caused by the Treatment with Platinum Analogues

“…Tinnitus and hearing loss have been observed in up to 31% of patients treated with initial intravenous cisplatin dose of 50 mg/m 2 [20, 21]. Transient hearing loss and mild audiometric abnormalities were observed in 30% of patients receiving 150 mg/m 2 of cisplatin [22, 23].…”

“…The mechanisms of cisplatin-induced damage to the outer hairy cells of the cochlea probably include the formation of reactive oxygen radicals and depletion of glutathione [24]. Other risk factors include simultaneous use of other potentially ototoxic agents (e.g., aminoglycosides), previous cranial irradiation, preexisting renal dysfunction, or inner ear damage [21, 23, 25, 26]. …”